On November 24, 2020 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, reported that it will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference (Press release, Akebia, NOV 24, 2020, View Source/news-releases/news-release-details/akebia-therapeutics-participate-piper-sandler-32nd-annual" target="_blank" title="View Source/news-releases/news-release-details/akebia-therapeutics-participate-piper-sandler-32nd-annual" rel="nofollow">View Source [SID1234571671]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

John P. Butler, President and Chief Executive Officer, and David A. Spellman, Senior Vice President and Chief Financial Officer, will participate in virtual one-on-one meetings on Thursday, December 3, 2020.

A recording of Akebia’s conference presentation is available via the Piper Sandler conference site as well as on the Investors section of the Company’s website at View Source, from November 24 to December 3, 2020.